Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Busulfan (Primary) ; Melphalan (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Filgrastim; Mesna; Topotecan; Vincristine
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacogenomic
- 15 Jul 2024 Status changed from active, no longer recruiting to completed.
- 05 Apr 2023 This study protocol has been amended as the phase of the study has been changed to Phase 1
- 01 Jun 2021 Results published in the Transplantation and Cellular Therapy